[go: up one dir, main page]

WO2004096197A3 - 5-aza-7-deazapurine nucleosides for treating flaviviridae - Google Patents

5-aza-7-deazapurine nucleosides for treating flaviviridae Download PDF

Info

Publication number
WO2004096197A3
WO2004096197A3 PCT/IB2004/001740 IB2004001740W WO2004096197A3 WO 2004096197 A3 WO2004096197 A3 WO 2004096197A3 IB 2004001740 W IB2004001740 W IB 2004001740W WO 2004096197 A3 WO2004096197 A3 WO 2004096197A3
Authority
WO
WIPO (PCT)
Prior art keywords
aza
pestivirus
flavivirus
host
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/001740
Other languages
French (fr)
Other versions
WO2004096197A2 (en
WO2004096197A8 (en
Inventor
Colla Paolo La
Gilles Gosselin
Frank Seela
David Dukhan
Frederic Leroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universita degli Studi di Cagliari
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universita degli Studi di Cagliari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universita degli Studi di Cagliari filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2004096197A2 publication Critical patent/WO2004096197A2/en
Publication of WO2004096197A3 publication Critical patent/WO2004096197A3/en
Publication of WO2004096197A8 publication Critical patent/WO2004096197A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-hepacivirus, anti-flavivirus or anti-pestivirus biologically active acyclic ester or pentofuranonucleoside that has a 5-aza-7-deazapurine nucleoside base. Also claimed are pharmaceutical compositions of the present invention that may be administered alone or in combination and/or alternation with another anti­viral agent, and a use of these nucleoside analogues in the manufacture of a medicament.
PCT/IB2004/001740 2003-05-02 2004-05-03 5-aza-7-deazapurine nucleosides for treating flaviviridae Ceased WO2004096197A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46746503P 2003-05-02 2003-05-02
US60/467,465 2003-05-02

Publications (3)

Publication Number Publication Date
WO2004096197A2 WO2004096197A2 (en) 2004-11-11
WO2004096197A3 true WO2004096197A3 (en) 2005-01-13
WO2004096197A8 WO2004096197A8 (en) 2005-04-14

Family

ID=33418448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001740 Ceased WO2004096197A2 (en) 2003-05-02 2004-05-03 5-aza-7-deazapurine nucleosides for treating flaviviridae

Country Status (1)

Country Link
WO (1) WO2004096197A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
AU2005314252B2 (en) 2004-12-06 2012-09-27 Siga Technologies, Inc. Compounds and methods for treating hemorrhagic fever viruses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
WO2001017518A2 (en) * 1999-09-09 2001-03-15 Zymetx, Inc. Method of treatment of influenza
WO2001060315A2 (en) * 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
WO2001017518A2 (en) * 1999-09-09 2001-03-15 Zymetx, Inc. Method of treatment of influenza
WO2001060315A2 (en) * 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. KOJIC-PRODIC ET AL: "Conformation and structure of 2-amino-8-(beta-D-ribofuranosylimidazoü1,2-a]-s-triazin-4-one (5-aza-7deaza guanosine), a potent antiviral nucleoside", BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, vol. 698, no. 2, 30 August 1982 (1982-08-30), pages 105 - 110, XP002301284 *
KIM ET AL: "Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogs of imidazo[1,2-a]-s-triazine", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 21, no. 9, 1978, pages 883 - 889, XP002151146, ISSN: 0022-2623 *
ROSEMEYER H ET AL: "5-AZA-7-DEAZA-2'-DEOXYGUANOSINE: STUDIES ON THE GLYCOSYLATION OF WEAKLY NUCLEOPHILIC IMIDAZO1,2-A-S-TRIZINYL ANIONS", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 52, no. 23, 13 November 1987 (1987-11-13), pages 5136 - 5143, XP000984065, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
WO2004096197A2 (en) 2004-11-11
WO2004096197A8 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2005009418A3 (en) Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2006000922A3 (en) 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
NO20025600D0 (en) Methods and compositions for the treatment of flaviviruses and pestiviruses
EP1669364A3 (en) Methods and compositions for treating hepatitis C virus
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
BR0312278A (en) 2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections
WO2006037028A3 (en) Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
EA200200778A1 (en) METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION
RU2011139180A (en) COMBINATION OF A NUCLEOSIDE INHIBITOR OF POLYMERASE AND A MACROCYCLIC INHIBITOR OF PROTEASE AND ITS APPLICATION FOR TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND DISTURBED HEPATIC FUNCTION
TW200500373A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EA200700362A1 (en) CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO.
WO2005065646A3 (en) Novel drug compositions and dosage forms
PT1387681E (en) Use of castanospermine derivatives for the treatment of hepatitis c
WO2004112720A3 (en) Antiviral compositions and methods of using the same
MXPA06007510A (en) Novel drug compositions and dosage forms of topiramate.
WO2004096197A8 (en) 5-aza-7-deazapurine nucleosides for treating flaviviridae
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
HUP0301451A3 (en) Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies
James Ribavirin approved for hepatitis C combination treatment
SE0001531D0 (en) Medication for the treatment of diseases caused by parasitic protozoa
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?
NZ600527A (en) Antiviral compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase